Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 588

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 588
---
 December 31, 2024 and 2023

    2024  
    2023 

    Net
    Revenue 
    $9,362,022  
    $2,532,499 

    Operating expenses: 

    Direct costs and expenses 
     5,983,475  
     1,740,884 
  
    Research and development 
     1,461,227  
     1,467,936 
  
    Clinical development 
     321,655  
     256,661 
  
    Selling, general and
    administrative 
     9,943,473  
     6,790,654 
  
    Depreciation
    and amortization 
     605,637  
     249,592 

    Total
    operating expenses 
     18,315,467  
     10,505,727 

    Loss
    from operations 
     (8,953,445) 
     (7,973,228)

    Other income (expense): 

    Interest income 
     17,610  
     122,131 
  
    Interest expense 
     (92,475) 
     (37,125)
  
    Other income 
     10,323  
     3,325 
  
    Other expense 
     (10,194) 
     (31,121)

    Loss
    before income taxes 
     (9,028,181) 
     (7,916,018)

    Income tax expense 
     (11,650) 
     (20,993)

    Net
    loss 
    $(9,039,831) 
    $(7,937,011)

    Net loss per common share, basic and diluted 
    $(0.75) 
    $(0.91)

    Weighted average common shares outstanding 
     12,125,029  
     8,747,509 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4

bioAffinity
Technologies, Inc.

Consolidated
Statements of Changes in Stockholders’ Equity

For
the Years Ended December 31, 2024 and 2023

    Convertible  
       
    Additional  
       
    Stockholders’ 

    Preferred
    Stock